Axsome Therapeutics had its Relative Strength (RS) Rating upgraded from 66 to 79 Thursday — a welcome improvement, but still short of the 80 or higher score you look for.
Can You Really Time The Stock Market?
This proprietary rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an RS Rating of above 80 as they begin their largest price moves. See if Axsome Therapeutics can continue to show renewed price strength and hit that benchmark.
Axsome Therapeutics is now considered extended and out of buy range after clearing a 105.00 buy point in a second-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Axsome Therapeutics reported 0% earnings growth last quarter. Revenue rose 72%.
The company holds the No. 124 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
